Genialis has raised $13 million to develop clinical biomarkers that predict patient response



Genialis, a computational precision medicine company that is unraveling complex biology to find new ways to treat disease, announced today that it has raised more than $13 million in Series A funding to transform how diseases are diagnosed and treatment decisions are made.

Taiwania Capital and Debiopharm Innovation Fund co-led the round, with previous investors First Star Ventures, Redalpine Venture Partners, and Pikas also participating. P5 Health Ventures and several Angels are among the new investors. Taiwania’s Ita Lu and Debiopharm’s Hamzeh Abdul-Hadi will join Genialis’ Board of Directors.

Genialis is developing next-generation patient classifiers that use machine learning and high-throughput omics data to understand underlying disease biology and predict how patients will respond to targeted therapies.

The Series A funds will be used to expand the company’s proprietary ResponderIDTM platform and build out its comprehensive collection of clinically validated biomarker models in order to provide pinpoint diagnoses for virtually every cancer patient.

Genialis has used ResponderID in collaboration with biopharma to analyze clinical trial data and inform future trial designs for a variety of investigational drugs to date. Genialis also collaborates with several leading diagnostic companies to commercialize next-generation biomarker assays.

On April 5, 2023, Genialis will present a poster at the Genomics in Precision Oncology Xchange in Boston. The following day, they will host a roundtable discussion at the Oncology Companion Diagnostics Xchange, which will also be held in Boston. Genialis will be attending AACR 2023 in Orlando, Florida, from April 14 to 19, where it will co-present a poster with OncXerna Therapeutics and Regeneron Pharmaceuticals.

Genialis is a computational precision medicine company that is deciphering complex biology in order to find new ways to treat disease.

Genialis’ machine-learning-driven disease modeling platform, ResponderIDTM, delivers actionable biomarkers and optimally positions novel drugs to accelerate translational research, streamline drug development, and ensure the best clinical care possible.

Genialis is trusted by pharmaceutical and diagnostics partners, and we work together to bring precision medicine to patients.

Related Stories